ArticlePlacenta2020
Concepts in preterm birth research: Interview with a stakeholder.
Article in Placenta, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Preterm birth continues to be a clinical problem of vast significance all over the world [1,2]. The complexities of the biology of preterm birth suggest a syndrome with multiple factors that synchronize rupture of membranes, uterine contraction, cervical dilation, and labor. Multiple genetic, environmental, and basic biological factors are associated with preterm birth. Despite many years of effort, we still do not completely understand preterm birth, the basic mechanisms underlying parturition, or the relationship(s) between the two. My position has always been that breakthroughs in this area will come from an inclusive, integrative, and interdisciplinary approach that hears the voices of multiple stakeholders, encompasses "outside the box" thinking and utilizes novel methodologies. To document the voices of stakeholders, alternative thinking and the seeds of development of novel methodologies, I have begun to interview stakeholders in preterm birth. This is an interview with Ramkumar Menon, MS, PhD, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine & Perinatal Research, The University of Texas Medical Branch at Galveston. Dr. Menon is past president and current Executive Director of PREBIC Global. He has surmounted considerable challenges to not only produce outstanding science from his own laboratory, but also to bring together collaborators and support from all over the world to bear upon the problem of preterm birth. What follows is an interview I did with him in 2014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.